Medicinal Chemistry Research最新文献

筛选
英文 中文
Pantoprazole as a potential repurposed drug targeting the adenosinergic system in esophageal cancer 泮托拉唑作为一种潜在的靶向食管癌腺苷能系统的药物。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-09-25 DOI: 10.1007/s00044-026-03618-2
Adriana Simioni, Rafael D Weimer, Julia B de Souza, Isadora V Citrini, Julia A da Rosa, Kaline Cardoso, Maria E Delawi, Luis FSM Timmers, Fernanda B Morrone
{"title":"Pantoprazole as a potential repurposed drug targeting the adenosinergic system in esophageal cancer","authors":"Adriana Simioni,&nbsp;Rafael D Weimer,&nbsp;Julia B de Souza,&nbsp;Isadora V Citrini,&nbsp;Julia A da Rosa,&nbsp;Kaline Cardoso,&nbsp;Maria E Delawi,&nbsp;Luis FSM Timmers,&nbsp;Fernanda B Morrone","doi":"10.1007/s00044-026-03618-2","DOIUrl":"10.1007/s00044-026-03618-2","url":null,"abstract":"<div><p>Esophageal cancer remains a major global health burden and is associated with poor prognosis. Adenosine signaling, particularly through CD73 and P1 receptors, contributes to tumor progression and immune modulation. Pantoprazole, a proton pump inhibitor widely used in clinical practice, has recently been suggested as a potential modulator of adenosinergic pathways. This study investigated the ability of pantoprazole to modulate adenosine signaling. In silico docking analyses were performed to assess the binding of pantoprazole to adenosine P1 receptors and CD73, followed by in vitro assays using esophageal adenocarcinoma (OE33) and squamous cell carcinoma (KYSE450) cell lines to evaluate cell growth, adenosinergic signaling, and tumor-related cellular functions following pantoprazole treatment. Docking analyses identified CD73 and P1 receptors, particularly A<sub>2A</sub>, as favorable molecular targets for pantoprazole. Pantoprazole significantly reduced proliferation and metabolic activity in both cell lines in a concentration-dependent manner, with pronounced inhibition of clonogenic survival in adenocarcinoma cells. Pantoprazole altered P1 receptor expression, particularly A<sub>2A</sub>, and pharmacological antagonism supported the involvement of these receptors in its antiproliferative effects. Additionally, pantoprazole modulated CD73 expression and reduced cell adhesion and MMP‑2 expression. These findings indicate that pantoprazole exerts antitumor effects by modulating the CD73–adenosine–P1 receptor axis, supporting its potential repurposing as an adjunctive strategy for the treatment of esophageal adenocarcinoma.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 10","pages":"2094 - 2108"},"PeriodicalIF":3.5,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00044-026-03618-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149056772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of pipernonaline from Piper retrofractum on memory disorder in mice and neurite outgrowth activity of PC12 cells. 胡椒肽对小鼠记忆障碍及PC12细胞神经突生长活性的影响。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-09-24 DOI: 10.1007/s00044-026-03617-3
Runa Fujimoto, Yuzuki Irie, Tohru Mitsunaga, Kosei Yamauchi
{"title":"Effect of pipernonaline from Piper retrofractum on memory disorder in mice and neurite outgrowth activity of PC12 cells.","authors":"Runa Fujimoto, Yuzuki Irie, Tohru Mitsunaga, Kosei Yamauchi","doi":"10.1007/s00044-026-03617-3","DOIUrl":"https://doi.org/10.1007/s00044-026-03617-3","url":null,"abstract":"<p><p>In this study, we discovered compounds comprising a piperidine skeleton in Piper retrofractum; the compounds exhibit PC12 dendrite elongation activity. Furthermore, we examined the structure-activity relationship by comparing the activities of the isolated compounds 1, 3-7. Among the isolated compounds, two alkaloids (6 and 7) displayed significant neurite outgrowth (NOG) effects in the presence of 5 ng/mL nerve growth factor (NGF) in a dose-dependent manner. Comparison of the activity of 3 (Pipercide; 1.8% NOG positive at 100 µM), 6 (Dehydropipernonaline; 21.1% NOG positive at 100 µM), and 7 (Pipernonaline; 24.3% NOG positive at 100 µM) (Nobiletin; 25.4% at 50 µM as positive control) demonstrated that the piperidine skeleton is key to NOG activity. Furthermore, the carbon chain length and number of double bonds influence NOG activity. Moreover, the Barnes maze test showed that oral administration of compound 7 in mice improved memory disorders induced by scopolamine and corticosterone. These results provide extremely valuable foundational knowledge for elucidating the cognitive function-improving effects of P. retrofractum, a food spice.</p>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Repurposing antifolates as G9a methyltransferase inhibitors for potential Alzheimer's disease therapeutics via 3D QSAR/pharmacophore mapping and experimental validations. 通过3D QSAR/药效团定位和实验验证,将抗叶酸盐作为G9a甲基转移酶抑制剂用于潜在的阿尔茨海默病治疗。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-09-24 DOI: 10.1007/s00044-026-03621-7
Abhisek Jana, Aina Bellver-Sanchis, Koushik Barman, Christian Griñán-Ferré, Deb Ranjan Banerjee
{"title":"Repurposing antifolates as G9a methyltransferase inhibitors for potential Alzheimer's disease therapeutics via 3D QSAR/pharmacophore mapping and experimental validations.","authors":"Abhisek Jana, Aina Bellver-Sanchis, Koushik Barman, Christian Griñán-Ferré, Deb Ranjan Banerjee","doi":"10.1007/s00044-026-03621-7","DOIUrl":"https://doi.org/10.1007/s00044-026-03621-7","url":null,"abstract":"<p><p>Herein, we report a systematic ML-embedded virtual screening strategy for the repurposing of antifolates (hTS inhibitors) targeting Histone Lysine Methyltransferase (G9a/EHMT2), with experimental validation. Three pharmacophore models (3D QSAR, Common Feature, and Interaction), derived from known G9a inhibitors, were used in a database mining of the 1120 hTS inhibitors from the ChEMBL database. Candidates were filtered using a multi-tier screening strategy based on fit values, drug-likeness, ADMET, and TOPKAT criteria, followed by molecular docking to assess interactions with G9a's active site, including compounds such as UNC0642 and Raltitrexed as references. The top candidates were selected for strong docking scores, the ability to form at least three hydrogen bonds, and interaction with the lysine-binding tunnel. Among these, Pemetrexed exhibited a binding mode similar to Raltitrexed, forming critical hydrogen bonds and pi interactions with residues Leu1086, Ser1084, Tyr1154, Arg1157, and Phe1158, indicating its potential as a G9a inhibitor. Further analyses of RMSD, RMSF, ROG, and protein-ligand interactions confirmed the stability of Pemetrexed, and MM-GBSA binding energy calculations, along with residue-wise decomposition analysis, supported its strong affinity for G9a. An in vitro assay of Pemetrexed revealed G9a inhibitory activity with an IC<sub>50</sub> of 304.90 nM, demonstrating its potency. Additionally, Pemetrexed exhibits lower activity against the G9a-like methyltransferase GLP than the references, confirming the compound's preferential activity for G9a over GLP. Furthermore, Pemetrexed improves the locomotor deficits associated with Aβ expression in C. elegans CL2006 worms in a dose-dependent manner, showing its potential as an epigenetic therapeutic for Alzheimer's Disease.</p>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An updated review of enantioselective syntheses and biological actions of carbanucleosides 碳核苷对映选择性合成及其生物作用的最新进展。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-09-24 DOI: 10.1007/s00044-026-03623-5
Sheila I. de Diego Saadia, Sergio H. Szajnman, Juan B. Rodriguez
{"title":"An updated review of enantioselective syntheses and biological actions of carbanucleosides","authors":"Sheila I. de Diego Saadia,&nbsp;Sergio H. Szajnman,&nbsp;Juan B. Rodriguez","doi":"10.1007/s00044-026-03623-5","DOIUrl":"10.1007/s00044-026-03623-5","url":null,"abstract":"<div><p>Carbocyclic nucleosides are nucleoside analogues where the oxygen atom of the furanose ring is replaced by a methylene group, in many cases a substituted methylene moiety, giving rise to metabolically stable nucleosides analogues that are recognized by the same enzymes that interact with canonical nucleosides. In this article, we were focused on the relevant features of the chemistry and biological properties of this family of compounds emphasizing synthetic aspects to access carbocyclic nucleosides enantioselectively and a comprehensive panorama of their biological properties. Molecular recognition outlook of enzymes of pharmacological importance are discussed. The influence of sugar conformation and puckering in modulating the biological activity and the use of carbanucleosides are illustrated.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 10","pages":"1975 - 2006"},"PeriodicalIF":3.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149035985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peptide-based allosteric modulators of AMPA receptors: design, docking and ligand-receptor interactions. 基于肽的AMPA受体变构调节剂:设计,对接和配体-受体相互作用。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-09-24 DOI: 10.1007/s00044-026-03615-5
Tatiana V Vyunova, Liudmila A Andreeva, Konstantin V Shevchenko, Valeriy P Shevchenko, Igor Y Nagaev, Andrey A Butylin, Mstislav I Lavrov, Vladimir A Palyulin, Pavel E Musienko, Nikolay F Myasoedov
{"title":"Peptide-based allosteric modulators of AMPA receptors: design, docking and ligand-receptor interactions.","authors":"Tatiana V Vyunova, Liudmila A Andreeva, Konstantin V Shevchenko, Valeriy P Shevchenko, Igor Y Nagaev, Andrey A Butylin, Mstislav I Lavrov, Vladimir A Palyulin, Pavel E Musienko, Nikolay F Myasoedov","doi":"10.1007/s00044-026-03615-5","DOIUrl":"https://doi.org/10.1007/s00044-026-03615-5","url":null,"abstract":"<p><p>Neurodegenerative diseases are one of the most pressing challenges of modern medicine, a problem from which no one is immune. Many medications used to treat dementia are ineffective in eliminating the root cause of pathogenesis, or exhibit a number of side effects. Great interest has been shown in positive allosteric modulators (PAMs) of AMPA receptors and PAM-43 is one of the most promising PAMs to date. Peptide allosteric modulators are another promising area of AMPA receptor PAMs. There are numerous cases where peptide-based drugs have a gentler effect and do not cause negative side effects or addiction with prolonged use. Here we designed and synthesized two peptide structures, potential PAMs of AMPA receptors. Our studies have shown that tetrapeptide WPPW and its derivative Boc-WPPW are stable enough to bind a target receptor and do bind to it. Molecular docking of the peptides and PAM-43 revealed several specific binding sites on AMPA receptor, some of which partially overlap. These peptides notably modulate the interaction of [<sup>3</sup>H]PAM-43 at various sites of its specific binding. WPPW partially blocks [<sup>3</sup>H]PAM-43 binding at both its specific sites (high- and low-affine) in a dose-dependent manner. At certain concentrations, Boc-WPPW enhances the exposure of additional binding sites of PAM-43 that may be located not only on AMPA receptors. The peptides WPPW and Boc-WPPW may be of interest as AMPA receptor potential allosteric modulators or cofactor molecules.</p>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence-assisted lead optimization in drug discovery: bridging computational advances and translational challenges. 人工智能辅助先导优化药物发现:弥合计算进步和转化挑战。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-09-17 DOI: 10.1007/s00044-026-03616-4
Fatma AlZahraa A A Mohamed, Ahmed Mohsen Kamal El-Sagheir
{"title":"Artificial intelligence-assisted lead optimization in drug discovery: bridging computational advances and translational challenges.","authors":"Fatma AlZahraa A A Mohamed, Ahmed Mohsen Kamal El-Sagheir","doi":"10.1007/s00044-026-03616-4","DOIUrl":"https://doi.org/10.1007/s00044-026-03616-4","url":null,"abstract":"<p><p>Lead optimization is a resource-intensive stage of drug discovery requiring the simultaneous optimization of potency, selectivity, pharmacokinetics, safety, and synthetic feasibility. Although artificial intelligence (AI) and machine learning (ML) have substantially advanced predictive modeling, virtual screening, de novo molecular design, and multiparameter optimization, their translation into routine medicinal chemistry remains challenging. This review critically examines current AI approaches for lead optimization, emphasizing the gap between computational benchmark performance and practical medicinal chemistry applications. Recent advances in graph neural networks (GNNs), transformer architectures, diffusion models, and chemical foundation models have expanded AI-assisted molecular design and property prediction. We further discuss emerging concepts including data-centric AI, uncertainty quantification, trustworthy AI, the AI optimization paradox, and the shift from molecular prediction toward scientific decision-making as key determinants of successful implementation. Despite increasing industrial adoption, AI remains dependent on high-quality experimental data, model generalizability, and rigorous experimental validation. We conclude that future progress will depend less on increasingly sophisticated algorithms than on trustworthy AI systems that improve scientific decision-making within iterative lead optimization workflows and ultimately enhance translational success in drug discovery.</p>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Probing novel azole-sulfonamide urea/thiourea conjugates as multitarget inhibitors of AChE and hCAs (I and II): synthesis, in vitro, and in silico studies. 探索新型唑-磺胺脲/硫脲缀合物作为乙酰胆碱酯和乙酰胆碱酯的多靶点抑制剂(I和II):合成,体外和硅研究。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-09-17 DOI: 10.1007/s00044-026-03619-1
İrfan Çapan, Çağan Yasa, Yeliz Demir, Metin Güzelcan, Mohammed T Qaoud, Yusuf Sert, İrfan Koca, İlhami Gülçin
{"title":"Probing novel azole-sulfonamide urea/thiourea conjugates as multitarget inhibitors of AChE and hCAs (I and II): synthesis, in vitro, and in silico studies.","authors":"İrfan Çapan, Çağan Yasa, Yeliz Demir, Metin Güzelcan, Mohammed T Qaoud, Yusuf Sert, İrfan Koca, İlhami Gülçin","doi":"10.1007/s00044-026-03619-1","DOIUrl":"https://doi.org/10.1007/s00044-026-03619-1","url":null,"abstract":"<p><p>A series of 30 novel azole-sulfonamide urea and thiourea conjugates was rationally designed and synthesized as potential multitarget inhibitors of acetylcholinesterase (AChE) and the human carbonic anhydrase isoforms hCA I and hCA II. The molecular design combined azole-based heterocyclic scaffolds with the classical sulfonamide zinc-binding pharmacophore through urea or thiourea linkers. The synthesized compounds were characterized by FT-IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, and high-resolution mass spectrometry and subsequently evaluated in vitro against the three target enzymes. Several derivatives exhibited potent nanomolar inhibitory activity. Compounds 11, 6, 26, and 16 were the most active AChE inhibitors, with IC₅₀ values of 23.89, 30.13, 34.65, and 36.47 nM, respectively. Compounds 25, 26, 29, and 20 displayed the strongest inhibition of hCA I, with IC₅₀ values ranging from 40.76 to 46.82 nM, whereas compounds 11 and 17 were the most active against hCA II, both exhibiting an IC₅₀ value of 57.75 nM. Selectivity analysis based on the IC₅₀(hCA I)/IC₅₀(hCA II) ratio indicated limited isoform discrimination overall, with selectivity indices ranging from 0.42 to 1.26. Most derivatives showed a modest relative preference toward hCA I, whereas compounds 13, 17, 18, and 21 displayed modest preference toward hCA II, with compound 17 showing the highest hCA II selectivity index (SI = 1.26). Notably, compounds 11 and 26 showed a well-balanced multitarget profile across all three tested enzymes. Molecular docking and MM-GBSA calculations suggested plausible binding modes involving hydrogen bonding, aromatic interactions, hydrophobic contacts, and, for selected carbonic anhydrase complexes, sulfonamide-mediated coordination with the catalytic Zn²⁺ ion. Overall, the experimental and computational findings identify azole-sulfonamide urea/thiourea conjugates as promising scaffolds for the further development of multitarget enzyme inhibitors and provide preliminary structure-activity insights for subsequent optimization.</p>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the therapeutic potential of Calotropis procera: from traditional applications to phytochemistry, pharmacology, and safety. 揭示原花椒的治疗潜力:从传统应用到植物化学、药理学和安全性。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-09-17 DOI: 10.1007/s00044-026-03613-7
Nitish Kumar, Rohit Singh Negi, Jyotirmayee Behera, Manjeet Kumar Sah Gond, Sunil Kumar Mishra
{"title":"Unveiling the therapeutic potential of Calotropis procera: from traditional applications to phytochemistry, pharmacology, and safety.","authors":"Nitish Kumar, Rohit Singh Negi, Jyotirmayee Behera, Manjeet Kumar Sah Gond, Sunil Kumar Mishra","doi":"10.1007/s00044-026-03613-7","DOIUrl":"https://doi.org/10.1007/s00044-026-03613-7","url":null,"abstract":"<p><p>Calotropis procera (Aiton) W.T. Aiton, a perennial shrub of the Apocynaceae family, is widely valued in Ayurveda, Unani, Siddha, and homeopathy for its broad therapeutic potential, attributed to a diverse phytochemical repertoire that includes alkaloids, triterpenoids, flavonoids, saponins, steroids, fatty acids, glycosides, and proteases. Traditionally, it is used to treat bronchitis, asthma, leprosy, eczema, elephantiasis, joint disorders, various skin ailments, and is also employed as a laxative, anthelmintic, and antiulcer agent. Phytochemical investigations of its latex, leaves, flowers, and stem bark reveal abundant terpenoids, cardenolides, steroids, and proteolytic enzymes, which underpin its antimicrobial, anti-inflammatory, analgesic, hypoglycemic, hepatoprotective, and wound-healing activities; notably, the stem bark demonstrates strong anti-inflammatory and gastroprotective effects. This review compiles and evaluates literature from PubMed, Google Scholar, and Web of Science up to November 2025, providing an integrated account of the plant's traditional uses, botanical characteristics, phytochemistry, pharmacology, and safety, while also incorporating comparative insights on the closely related species Calotropis gigantea. Given its rich bioactive profile and multifaceted pharmacological value, C. procera emerges as a promising candidate for future drug development, warranting detailed mechanistic studies, extract standardization, and evidence-based integration into modern healthcare systems.</p>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
O-methylation of phenolic natural products: translational insights from resveratrol. 酚类天然产物的o -甲基化:来自白藜芦醇的翻译见解。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-09-10 DOI: 10.1007/s00044-026-03614-6
Solomon Habtemariam
{"title":"O-methylation of phenolic natural products: translational insights from resveratrol.","authors":"Solomon Habtemariam","doi":"10.1007/s00044-026-03614-6","DOIUrl":"https://doi.org/10.1007/s00044-026-03614-6","url":null,"abstract":"<p><p>O-Methylation is a rational optimisation strategy for resveratrol in which phenolic hydroxyl groups are replaced with methoxy groups to increase lipophilicity, metabolic stability, membrane permeability, and systemic exposure. The resulting pharmacokinetic (PK) improvements may contribute to enhanced pharmacodynamic (PD) effects, as exemplified by methoxylated stilbenes such as pterostilbene, which generally retain the core biological activities of resveratrol while mostly exhibiting greater in vivo efficacy. However, extending this concept to other phenolic natural products shows that improved PK does not uniformly translate into improved PD. Examples from flavonoids, phenolic acids, lignans, ellagitannins, and classical pharmacological analogues illustrate that, although O-methylation frequently enhances metabolic stability and bioavailability, PD outcomes depend on intrinsic target interactions, therapeutic mechanisms, and, in some cases, microbiota-dependent bioactivation. In some examples, O-methylation may even improve PK while reducing intrinsic pharmacodynamic potency. Increased lipophilicity also presents formulation challenges, particularly in aqueous nutraceutical and functional beverage systems, highlighting the need for advanced delivery strategies such as nanoemulsions, nanoliposomes, micellar systems, and cyclodextrin inclusion complexes. Using resveratrol as a model, this review critically evaluates the available, predominantly preclinical, evidence on the relationship between O-methylation, PK, and PD, identifies important exceptions to this relationship, and discusses the implications for pharmaceutical, nutraceutical, and functional beverage development.</p>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":" ","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148928619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD) Centanafadine (Simtriyo®):一种被批准用于治疗注意力缺陷/多动障碍(ADHD)的新型三重再摄取抑制剂。
IF 3.5 4区 医学
Medicinal Chemistry Research Pub Date : 2026-08-25 DOI: 10.1007/s00044-026-03612-8
Longqin Hu
{"title":"Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD)","authors":"Longqin Hu","doi":"10.1007/s00044-026-03612-8","DOIUrl":"10.1007/s00044-026-03612-8","url":null,"abstract":"<div><p>Centanafadine (Simtriyo<sup>®</sup>, <b>3</b>) is a recently approved therapy for attention-deficit/hyperactivity disorder (ADHD) that introduces a first-in-class triple reuptake inhibition mechanism. Featuring a naphthyl group and a rigid azabicyclic scaffold, centanafadine functions as a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) with a potency profile of NET &gt; DAT &gt; SERT. Unlike flexible phenethylamine stimulants such as (meth)amphetamine (<b>1</b>), which enter presynaptic neurons and actively trigger monoamine release, or piperidine derivatives like methylphenidate (<b>2</b>), which selectively block dopamine and norepinephrine reuptake, centanafadine inhibits all three monoamine transporters without inducing neurotransmitter release. Centanafadine represents a modern medicinal chemistry strategy aimed at managing ADHD symptoms through combined catecholaminergic and serotonergic mechanisms, offering sustained efficacy while potentially mitigating the abuse liability, insomnia, and cardiovascular risks typical of traditional psychostimulants.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 9","pages":"1548 - 1552"},"PeriodicalIF":3.5,"publicationDate":"2026-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00044-026-03612-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148817023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书